Why Indication-Specific Thinking Is Holding Back Healthcare Insight

In healthcare, decisions are often grounded in deep indication-specific expertise. That expertise is valuable. But it can also create blind spots.

Teams are frequently asked some version of: “Do you have experience in this exact indication?” It’s a valid and expected question. Yet the same teams often find themselves surprised when the market moves in ways they didn’t anticipate.

The reason is simple. Most meaningful shifts don’t originate in isolation. They tend to emerge elsewhere first—within a different therapeutic area or another part of the healthcare ecosystem entirely. By the time those shifts are visible within a single indication, the window to respond may already be narrowing.

The Risk of Indication-Centric Thinking

There is a natural comfort in working within a familiar space. Known stakeholders, established dynamics, and a history of prior research create a sense of confidence. But that familiarity can also reinforce existing assumptions.

When teams stay too close to their own indication, it becomes easier to believe that what is happening is unique—that their market will behave differently, or that the same rules do not apply. In reality, many of the forces shaping healthcare markets are not indication-specific. They are structural.

We’ve seen this play out repeatedly:

• GLP-1s extending beyond their original use cases
• Modality shifts redefining treatment expectations
• Biosimilars reshaping not just pricing, but confidence and adoption

In each case, the broader implications were visible before they fully materialized within any single indication.

What Actually Drives Meaningful Insight

There is a tendency to equate expertise with indication familiarity. In practice, what drives strong healthcare research is not whether a team has worked in a specific disease area before, but how they approach the problem.

At its core, healthcare research requires rigor. That rigor is reflected not only in study design or clinical understanding, but in how the full ecosystem is considered.

Decisions in healthcare do not happen in isolation. They are shaped by a network of stakeholders:

• Physicians and clinical teams
• Office staff and care coordinators
• Payers and access decision-makers
• Pharmacists and distribution channels
• Patients and caregivers navigating real-world use

In complex areas such as oncology and immunology, that ecosystem becomes even more layered, involving infusion centers, multidisciplinary teams, and reimbursement structures. While the specifics may vary by indication, the underlying dynamics do not. The structure remains consistent.

Understanding that structure, and how it behaves, is often more valuable than familiarity with any single indication.

Where New Thinking Actually Comes From

One of the most effective ways to uncover meaningful insight is to look beyond the immediate indication and ask: Where else has this dynamic already played out?

More often than not, it has.

In one case, a client sought to understand how payers might respond to a new therapy entering a market with well-established competitors. Rather than limiting the analysis to that indication, similar scenarios were examined across other categories.

In HIV, for example, a new entrant improved patient adherence, which in turn began to shift payer behavior. The shift was not driven by the indication itself, but by what adherence represented—more consistent outcomes and a clearer value story.

That insight translated directly. It reframed access not as a fixed barrier, but as something influenced by real-world patient behavior.

Similar patterns emerge across the market:

• When oral therapies enter categories dominated by injectables, adoption is often driven as much by patient and provider behavior as by clinical differentiation
• When biosimilars enter the market, the impact extends beyond pricing to influence payer strategy, provider confidence, and pharmacy dynamics

These are not isolated events. They are recurring patterns.

The signal rarely starts where teams are looking.

Rethinking What “Experience” Really Means

Experience matters. The question is what kind of experience leads to better decisions.

Is it having worked within a single indication before? Or is it understanding how markets evolve, how stakeholders behave, and how patterns repeat across different contexts?

Prior indication experience can reduce perceived risk. But it can also reinforce what is already known. The greater risk is missing what is changing, and that rarely comes from staying within the same frame of reference.

Effective research partners do not need to begin with complete indication fluency. They need to know how to build it quickly and thoughtfully.

That process starts early:

• Developing an informed view of the landscape before a project is fully defined
• Identifying key stakeholders and ecosystem dynamics
• Continuously testing and refining assumptions as research progresses
• Grounding insights in real-world context, not just stated feedback

By the time recommendations are delivered, they should feel specific, relevant, and actionable—not like they are coming from a team still getting up to speed.

What This Means for Healthcare Decision-Makers

For teams navigating increasingly complex and fast-moving markets, this shift in perspective has practical implications:

• Broaden how markets are evaluated beyond a single indication
• Look for analogous situations across therapeutic areas to anticipate change
• Consider behavioral and ecosystem dynamics alongside clinical and economic factors
• Evaluate research partners based on how they approach problems, not just where they have worked before

Markets will continue to evolve. New dynamics will emerge, often in places that are easy to overlook.

The next meaningful shift in your market is unlikely to announce itself clearly—or originate where you are already focused.

So the more useful question may not be:

“Have you done this exact thing before?”

But rather:

“Can you help us see what we’re not seeing yet?”

About KS&R

KS&R is a nationally recognized strategic consultancy and marketing research firm that provides clients with timely, fact-based insights and actionable solutions through industry-centered expertise. Specializing in Technology, Business Services, Telecom, Entertainment & Recreation, Healthcare, Retail & E-Commerce, and Transportation & Logistics verticals, KS&R empowers companies globally to make smarter business decisions. For more information, please visit www.ksrinc.com.